Clinical trials recruiting for Breast Cancer Metastatic
32
Recruiting trials
28
US states with sites
13
Countries
3%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Abemaciclib | 3 |
| Avasopasem | 1 |
| BCNU | 1 |
| Bevacizumab | 1 |
| Capecitabine | 1 |
| Cyclophosphamid | 1 |
| Cyclophosphamide | 1 |
| Dalpiciclib | 1 |
| ES2B-C001 | 1 |
| Eribulin | 1 |
| Evorpacept (ALX148) | 1 |
| Exemestane 25 MG | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 7 |
| Texas | 4 |
| Florida | 3 |
| Georgia | 3 |
| Massachusetts | 3 |
| North Carolina | 3 |
| Ohio | 3 |
| Washington | 3 |
| Arizona | 2 |
| California | 2 |
| Connecticut | 2 |
| Illinois | 2 |
Top cities
New York, New York 5Atlanta, Georgia 3Boston, Massachusetts 3Canton, Ohio 3Dallas, Texas 3Houston, Texas 2Miami, Florida 2New Haven, Connecticut 2Omaha, Nebraska 2Orlando, Florida 2
Self-screener
Recruiting trials
- 21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
- A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
- A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
- A Real World Study of Sacituzumab Govitecan
- A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
- Decision Support Tool for Patients With Advanced Breast Cancer
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
- Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
- Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
- HER2-PET Imaging in HER2-low Breast Cancers
- HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
- Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer
- Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,
- Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
- PIK3CA Mutational Status Assessment
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
- Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- Sapu003 in Advanced mTOR-sensitive Solid Tumors
- Screening For BCRL In Targeted Therapy For Breast Cancer
- Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
- Target-specific immunoPET Imaging of Breast Cancer
- To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
- Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Related conditions
Trials recruiting for Breast Cancer Metastatic often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Breast Carcinoma 74Breast Cancer Stage IV 14Breast Neoplasms 105Ovarian cancer 118Metastatic breast cancer 131Hormone Receptor Positive Breast Cancer 24HER2 Negative Breast Carcinoma 15HER2-negative Breast Cancer 57Breast Neoplasm 20
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Breast Cancer Metastatic trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.